ÂÜÀòÂÒÂ×

Martin Dalziel is a highly experienced scientific director at Oxford PharmaGenesis since June 2014, leading health technology assessment (HTA) efforts for the UK, Ireland, and globally, specializing in oncology and cardiovascular disease. Previously, Martin held various consultancy roles focusing on HTA submissions, analyses, and manuscript writing. Martin's academic background includes a senior postdoctoral fellow/biochemistry lecturer position at the University of Oxford, and extensive postdoctoral research experience at institutions such as CBM - CNRS, Cancer Research UK, and Roswell Park Cancer Institute. Martin holds a PhD in Immunology/Glycobiology from St George's, University of London, and a BSc (Hons) in Molecular Biochemistry from Glasgow Caledonian University.